AR Variant Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?

AR Variant Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome? Clin Cancer Res. 2018 Dec 27;: Authors: Dehm SM, Montgomery B, Plymate SR Abstract CTCs biomarkers may become indicators for selection of therapy. The presence of AR variant positive CTCs may be markers indicating need for switching therapy. Methods for AR variant mRNA isolation from CTCs and confirmation of expression are critical factors needed for these techniques to be clinically applicable. PMID: 30591516 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research